LPCN 1148 Phase 2 Results to be Presented at 2024 EASL

Lipocine, a biopharmaceutical firm, has announced that findings from the Phase 2 trial of its drug LPCN 1148 will be highlighted in a late-breaking oral presentation at the EASL Congress 2024, scheduled from June 5 to 8 in Milan, Italy. The study focuses on the effects of oral LPCN 1148 on sarcopenia and hepatic encephalopathy in cirrhosis patients over a period of 52 weeks.

Dr. Arun J. Sanyal, a prominent figure in liver disease and metabolic health, will present the results during the Late Breaker session on June 8th, from 14:00 to 15:30 CEST, with the presentation set for 15.15 CEST in the Gold Room. The abstract, numbered LP139, underscores the potential of LPCN 1148, which contains testosterone laurate, in addressing critical unmet needs for cirrhosis patients. These include enhancing muscle mass, life quality, reducing episodes of hepatic encephalopathy, and improving post-transplant results.

Lipocine utilizes a unique technology platform to enhance the oral delivery of therapeutics, aiming to create distinctive CNS disorder treatments. The company is in the process of developing a range of drug candidates and is seeking partnerships for some. Their pipeline includes LPCN 1154 for postpartum depression, LPCN 2101 for epilepsy, LPCN 2203 for essential tremor, and LPCN 2401, a combination therapy for chronic weight management. Additionally, they are exploring opportunities for LPCN 1107, aimed at preventing preterm birth, and LPCN 1144 for non-cirrhotic NASH treatment.

TLANDO, another Lipocine development containing testosterone undecanoate, has received FDA approval for treating hypogonadism in adult males. The company's commitment to innovation and addressing significant medical needs is evident through their diverse and promising pipeline.